A 63-year-old man with chronic spontaneous urticaria

Gordon L. Sussman MD, Jacques Hebert MD, F. Estelle R. Simons MD

A 63-year-old man weighing 80 kg was referred to a university hospital allergy clinic with a 16-year history of generalized hives (itchy wheals with associated swelling) that occurred almost every day (Figure 1). Individual wheals lasted less than 24 hours. The patient restricted his diet because he thought that certain foods might be triggering the hives. He had difficulty sleeping because of constant, severe itching. His quality of life was poor.

The patient’s medications for the hives included hydroxyzine 25–200 mg total daily dose, supplemented with various nonprescription H1-antihistamines as needed, and prednisone 5–40 mg/d. He was also taking daily doses of rosvastatin 20 mg, valsartan 80–160 mg and clopidogrel 75 mg following a myocardial infarction, for which he had undergone angioplasty with a stent. His history also included reduced bone density and surgical repair of an abdominal aortic aneurysm.

Results of blood tests ordered in the past by his family physician and several consultants to rule out underlying diseases had consistently been within normal limits (see Appendix 1, at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.150154/-/DC1).

In the previous year, the patient had received five courses of prednisone and had visited the emergency department of his community hospital several times because of debilitating exacerbations of hives and intolerable itching.

First-generation H1-antihistamines did not consistently relieve his itching and whealing, although they caused sedation. At different times, besides hydroxyzine, the patient took diphenhydramine 25–200 mg total daily dose or doxepin 25–125 mg total daily dose, as well as second-generation H1-antihistamines, including cetirizine 10–40 mg and loratadine 10 mg.

From time to time, an H2-antihistamine (ranitidine 300 mg/d) or a leukotriene antagonist (montelukast 10 mg/d) had been added, without relief. Similarly, trials of hydroxychloroquine 400 mg/d followed by cyclosporine 300 mg/d, each used for two months, gave no relief. Intravenous gamma globulin treatment gave some relief, but it was stopped because of a hemolytic reaction. A chronologic account of the patient’s medication history is found in Appendix 1.

On examination in the allergy clinic, the patient had generalized confluent hives. His complete blood count, erythrocyte sedimentation rate and thyroid antibody test results (antithyperoxidase) were within normal limits. No other investigations were performed.

The patient was asked to monitor hives and itching daily for one week using a validated weekly Urticaria Activity Score (UAS7) (Box 1). His score of 42, the maximum weekly UAS7 score, indicated severe disease.

Given the poor response to previous medications, omalizumab 150 mg was administered monthly by subcutaneous injection. Cetirizine 20 mg/d was started again. Prednisone was continued in tapering doses. Within a week, the hives and itching had almost disappeared, as reflected in his daily UAS7 scores. Subsequently, the patient stopped taking prednisone and maintained low daily UAS7 scores. His sleep quality, sleep duration and work productivity improved. He responded well to each omalizumab injection; however, breakthrough urticaria often occurred six to eight weeks after the injections.

Competing interests:
Gordon Sussman declares involvement in research funded by grants from Novartis, Merck, Stallergenes, AstraZeneca, DBV Technologies and CSL Behring, and he declares receiving consultancy fees and speaker fees from Novartis. Jacques Hebert declares involvement in research funded by grants from Novartis, Boehringer, Merck, AstraZeneca, Circassia Ltd., Pfizer and DBV Technologies. The authors participated in the development of the guideline on which this article is based. No other competing interests were declared.

Correspondence to: Gordon Sussman, gsussman@sussmanresearch.com CMAJ 2016. DOI:10.1503/cmaj.150154

Key points

- According to the new urticaria classification system, “chronic spontaneous urticaria” has replaced the term “chronic idiopathic urticaria.”
- New validated, easy-to-use instruments, such as the Urticaria Activity Score (UAS7), are available to help patients quantify urticaria and itching on a daily basis.
- Based on a 2014 international urticaria guideline, the recommended first-line treatment of chronic spontaneous urticaria is a nonimpairing, nonsedating H1-antihistamine, such as desloratadine or cetirizine.
- Recommended second-line treatment is up-dosing (to two, three or four times the licensed dose) with a nonimpairing, nonsedating H1-antihistamine, such as desloratadine or cetirizine.
- Recommended third-line treatment of refractory chronic spontaneous urticaria includes omalizumab by monthly subcutaneous injection until remission occurs, or cyclosporine, although the latter appears to be less effective for inducing remission and may cause more adverse events.
Three years later, the chronic spontaneous urticaria again became severe and difficult to treat, requiring longer courses and higher doses of prednisone. The omalizumab dose was increased to 300 mg given monthly. Urticaria control, confirmed by low UAS7 scores, was subsequently maintained at this dosage.

Discussion

Chronic urticaria is urticaria that lasts for more than six weeks. It affects 0.5%–1% of the general population. Although about 50% of patients experience spontaneous remission within a year after onset, 10%–25% have recurrent urticaria for five years or more. Concomitant angioedema occurs in as many as two-thirds of patients.

According to expert international consensus, the new term “chronic spontaneous urticaria,” reflecting an endogenous, unidentifiable cause, has replaced the term “chronic idiopathic urticaria” (Box 2). Also, the term “chronic inducible urticaria” has replaced “chronic physical urticaria.”

Chronic inducible urticaria can occur independently from or concomitantly with chronic spontaneous urticaria. The thresholds for common stimuli that induce whealing, such as dermographism or cold, can now be tested using standardized instruments.

In contrast, acute urticaria, which affects as many as 30% of the general population, lasts from a few hours or days to six weeks and remits spontaneously. Often it is triggered by a viral infection or exposure to an allergen, especially in children. Relevant allergy tests are warranted if the history suggests atopy.

Pathophysiology

Chronic spontaneous urticaria often has an autoimmune cause. Antibodies to the α component of the immunoglobulin E (IgE) receptor on mast cells are identified in about 45% of affected patients; however, this test is neither widely available nor specific for chronic spontaneous urticaria. Thyroid antibodies are found in about 25% of patients with chronic spontaneous urticaria, but treatment of the thyroid disease does not typically relieve the urticaria. Although most patients with chronic spontaneous urticaria never have a specific cause identified, this does not affect their treatment or outcome.

Investigations

In chronic spontaneous urticaria, by consensus of experts, only a few routine diagnostic tests are recommended. A thorough history and physical examination are essential. Limited testing might consist of a complete blood count and measurement of inflammatory markers, including C-reactive protein or the erythrocyte sedimentation rate. This approach identifies patients who need further investigations. Allergy tests are usually not indicated, because food allergens seldom trigger chronic urticaria.

New instruments used in assessment

Chronic spontaneous urticaria causes substantial morbidity and negatively affects sleep, work, school and social activities. New instruments have been developed to quantify disease severity. Urticaria guidelines recommend use of the validated UAS7 score, in which the patient records severity of itching and number of wheals once daily (Box 1). A weekly score of less than 7 indicates complete control of disease, and a weekly score greater than 28 indicates severe disease.
activity. In clinical practice, use of the UAS7 score maximizes the information gathered at patient assessments and allows for efficient use of resources and time.²⁻⁴

New recommendations for treatment

The treatment goal in all types of urticaria is complete relief of pruritus, whealing and swelling (Figure 3). Treatment continues until the disease remits. Exacerbating factors, including emotional stress or ingestion of nonsteroidal anti-inflammatory drugs, should be minimized.²⁻³

First-line treatment

Second-generation H₁-antihistamines, such as desloratadine or cetirizine, are recommended as the cornerstone of urticaria treatment, based on evidence from high-quality randomized controlled trials (RCTs). Evidence-based recommendations include taking a second-generation H₁-antihistamine daily rather than intermittently, and not using more than one type of H₁-antihistamine on the same day.²⁻³

First-generation, sedating H₁-antihistamines are used empirically, as most of them were introduced before the era of RCTs. They are no longer recommended for use in chronic urticaria.²⁻³ Their potential adverse effects include reduction of rapid eye movement-sleep and impairment of cognitive function, including learning and memory. In patients with urticaria, the widespread belief that sleep is aided by addition of a sedating first-generation H₁-antihistamine such as hydroxyzine at bedtime is not supported by the available evidence.⁵⁻⁶

Second-line treatment

Findings from RCTs have shown that daily treatment with two to four times the licensed dose of many second-generation H₁-antihistamines increases efficacy without increasing adverse events.²⁻³,⁷⁻⁹ If this fails, the addition of montelukast for three to four weeks is recommended, although this is based on RCTs showing minimal benefit.²⁻³,¹⁰,¹¹ The use of H₁-antihistamines is no longer recommended: a Cochrane review found that the evidence for their use consisted of old studies with high or unclear risk of bias.²⁻³,¹⁰,¹¹

Refractory chronic spontaneous urticaria

Chronic spontaneous urticaria that fails to respond to second-line treatment needs additional pharmacotherapy. Many medications previously used as third-line treatment are no longer recommended for treatment of refractory chronic spontaneous urticaria.²⁻³,¹⁰,¹¹ Use of most third-line medications was based on case series (e.g., for sulfasalazine, methotrexate, colchicine, tacro-limus, mycophenolate and intravenous immune globulin) or on small RCTs (e.g., for hydroxychloroquine and dapsone). Several RCTs have shown efficacy of cyclosporine; however, because of potential nephrotoxic effects, patients taking cyclosporine require regular monitoring of blood pressure, renal function and cyclosporine levels.²⁻³,¹⁰,¹¹

Omalizumab, an anti-IgE monoclonal antibody, is the best studied medication for severe chronic spontaneous urticaria refractory to H₁-antihistamine treatment. It was licensed in 2014 on the basis of findings from five large, methodologically sound RCTs.¹²⁻¹⁴ In these studies, omalizumab doses of 300 mg, 150 mg and 75 mg given by subcutaneous injection every four weeks were significantly more effective than placebo. The 300-mg dose was significantly more effective than the 150-mg dose, and both of these doses were more effective than the 75-mg dose in relieving itching and whealing. Dosing was not based on patient weight or total IgE level, in contrast to omalizumab dosing for severe persistent asthma.¹²⁻¹⁴ In these RCTs, the proportion of patients who had one or more

Box 1: Urticaria Activity Score (UAS7)*

| Score | Wheals | Pruritus |
|-------|--------|---------|
| 0     | None   | None    |
| 1     | Mild (< 20 wheals/24 h) | Mild (present but not annoying or troublesome) |
| 2     | Moderate (20–50 wheals/24 h) | Moderate (troublesome but does not interfere with normal daily activity or sleep) |
| 3     | Intense (> 50 wheals/24 h or large confluent areas of wheals) | Intense (severe pruritus, sufficiently troublesome that it interferes with normal daily activity or sleep) |

*The UAS7 score is used to assess disease activity in patients with chronic spontaneous urticaria. The maximum daily score is 6. The maximum weekly score is 42. Access the UAS7 at http://urticaria.org.br/informacoes-uteis/uas/?lang=en.

Box 2: Classification of chronic urticaria*¹¹

Chronic spontaneous urticaria

• Lasting more than six weeks

Inducible urticaria

• Occurs in response to an identifiable trigger

Subtypes of chronic urticaria:

• Physical urticaria (dermographism, cold urticaria, delayed pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema)
• Cholinergic urticaria (hives from sweating, exercise or anxiety)
• Contact urticaria
• Aquagenic urticaria

*Urticaria presents with itchy wheals that may or may not be accompanied by swelling. Acute urticaria lasts less than six weeks.
Practice

Interleukin-1

Histamine and other mast cell mediators

Wheals and swelling

Recurrent unexplained fever?
Joint/bone pain? Malaise?

Autoinflammatory disease suspected?

Average wheal duration > 24 h?

Signs of vasculitis in biopsy?

Are symptoms inducible?

Provocation test result?

Acquired/hereditary autoinflammatory disease

Urticarial vasculitis

Chronic spontaneous urticaria

Chronic inducible urticaria

Recurrent unexplained fever?
Joint/bone pain? Malaise?

Figure 2: Algorithm for differential diagnosis of wheals and swelling. Adapted, with permission, from Zuberbier and colleagues.

Figure 3: Algorithm for the treatment of chronic spontaneous urticaria. Available evidence does not support use of first-generation impairing, sedating H₁-antihistamines, H₂-antihistamines or monotherapy with montelukast. The only anti-inflammatory or immunosuppressant agents that have been appropriately evaluated in randomized controlled trials are omalizumab and cyclosporine (see text for details). *Increase the standard dose to up to 40 mg of cetirizine or 20 mg of desloratadine if there is no response. †Can cause sedation at higher doses. ‡Oral corticosteroid such as prednisone 0.3–0.5 mg/kg or equivalent, for a maximum of 2–4 weeks, with tapering. Adapted, with permission, from Zuberbier and colleagues.
adverse events was similar across all treatment groups, including the placebo group. Anaphylaxis was not reported, in contrast to anaphylaxis reported after omalizumab injection in patients with asthma.

The mechanism of action of omalizumab in chronic spontaneous urticaria is related to its ability to decrease free IgE in the blood and interstitial space and prevent IgE binding to mast cells without cross-linking of the high-affinity IgE receptor. This action reduces the proliferation and survival of mast cells, increases the threshold for release of mediators from mast cells, and reduces the ability of mast cells to synthesize and store de novo mediators of inflammation.

In the clinical setting, omalizumab 150 mg subcutaneously induces complete remission in about 30% of patients with severe chronic spontaneous urticaria after the first dose, and in as many as 70% after additional doses. Monthly doses are required to maintain disease control in most patients.

Omalizumab is currently indicated for chronic spontaneous urticaria refractory to H1-antihistamine treatment in patients 12 years of age and older; however, it has also been shown to induce remission in children.

For rescue medication during severe exacerbations of chronic spontaneous urticaria, an orally administered corticosteroid, such as prednisone, should be prescribed for short-term use.

Cyclosporine is recommended as a relatively low-cost third-line treatment alternative to omalizumab. Given the high cost of omalizumab injections and the potential long-term morbidity of chronic spontaneous urticaria refractory to H1-antihistamine treatment, cost–benefit studies evaluating direct and indirect costs of omalizumab treatment compared with cyclosporine and other interventions are urgently needed.

References
1. Maurer M, Bindseil-Jensen C, Gimenez-Arnau A, et al. Chronic idiopathic urticaria is no longer idiopathic: Time for an update! Br J Dermatol 2015;172(Suppl 1):150-5.
2. Zuberbier T, Aberer W, Asero R, et al. Guidelines for the diagnosis, classification, and management of urticaria: report of the EAACI/GA2LEN-EDF/WAO guideline development group. J Invest Dermatol 2014;134:2284-307.
3. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014;69:865-75.
4. Mylne JK, Zarlewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy 2014;69:866-87.
5. Simons FER, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011;128:1139-50.e4.
6. Staevska M, Gugutkova M, Lazarova C, et al. Night-time sedating H1-antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. Br J Dermatol 2014;171:148-54.
7. Kavosh ER, Khan DA. Second-generation H1-antihistamines in chronic urticaria: an evidence-based review. J Allergy Clin Immunol 2015;132:637-42.
8. Sharma M, Bennett C, Cohen SN, et al. H1-antihistamines for chronic spontaneous urticaria. Cochrane Database Syst Rev 2014;11:CD006137.
9. Staevska M, Popov TA, Kealimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010;125:676-82.
10. Khan DA. Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use. J Allergy Clin Immunol Pract 2013;1:433-40.e1.
11. Mitchell S, Balb MM, Samuel M, et al. Systematic review of treatments for chronic spontaneous urticaria with inadequate response to licensed first-line treatments. Int J Dermatol 2015;54:1088-104.
12. Maurer M, Rosen K, Hsieh H-J, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924-35.
13. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013;132:101-9.
14. Saini SS, Bindseil-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1-antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015:135:67-75.
15. Urgert MC, van den Elzen MT, Knulst AC, et al. Omalizumab in patients with spontaneous urticaria: a systematic review and GRADE assessment. Br J Dermatol 2015;173:404-15.
16. Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol 2015;135:337-42.
17. Sussman O, Hober B, Barron C, et al. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol 2014;112:170-4.
18. Netchiporouk E, Nguyen CH, Thuraisingh T, et al. Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series. Pediatr Allergy Immunol 2015;26:585-8.

Affiliations: Department of Clinical Immunology and Allergy, and Department of Medicine (Sussman), University of Toronto, Toronto, Ont.; Centre de recherche appliqué en allergie de Quebec and Centre hospitalier de l’Université Laval (Hebert), Quebec, Que.; Department of Pediatrics and Child Health, and Department of Immunology (Simons), University of Manitoba, Winnipeg, Man.

Contributors: Gordon Sussman and F. Estelle Simons played leadership roles in the project and acted to ensure the quality and coherence of the manuscript. Gordon Sussman prepared the first draft of the manuscript, and all of the authors revised it critically for important intellectual content. All of the authors approved the final version to be published and agreed to act as guarantors of the work.

Acknowledgements: The authors acknowledge the secretarial assistance provided by Lori McNiven, Health Sciences Centre, Winnipeg, Man., and Corey Saperia, Gordon Sussman Clinical Research, Inc., Toronto, Ont.